Formulation Development
LYOPHILIZATION - Process Monitoring During Freeze-Drying
Gregory A. Sacha, PhD, describes the devices used for process monitoring and how they can be used to detect end points during the process.
FORMULATION FORUM - Application of Nano-Emulsion Technology to Address Unmet Medical Needs: A Case Study of Clopidogrel IV by 505(b)(2) Pathway
Jim Huang, PhD, presents a case study on how the EmulSol technology produces stable, optically clear nano-emulsions without the use of organic solvents and with minimal use of surfactants using a high-pressure or microfluidic homogenization process.
EXECUTIVE INTERVIEW - FSD Pharma Inc.: Is Ultra Micro-PEA the Best Untold Story in Pharma?
Raza Bokhari, MD, CEO of FSD Pharma, discusses how acquiring Prismic will benefit FSD, what makes the ultra-micronized platform unique, and how ultramicro-PEA could be the answer to ending the opioid epidemic.
GLOBAL REPORT - 2019 Global Drug Delivery & Formulation Report: Part 3, Notable Drug Delivery & Formulation Transactions & Technologies of 2019
In part 3 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on several notable drug delivery and formulation transactions and technologies.
Almac Group’s Comprehensive Service Offerings to Support Expedited COVID-19 Research Programs & Treatments
Almac Group is an established contract development and manufacturing organization (CDMO) providing an extensive range of integrated services across the drug development lifecycle to the…
Quotient Sciences & CytoAgents Accelerate Potential Treatment for COVID-19 Cytokine Storm
A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was recently announced today by Quotient Sciences, a leading…
WEBINAR - Developing an Oral Modified-Release (MR) Formulation: Challenges & Considerations for Achieving Success
Please join Quotient Sciences’ Vice President of Pharmaceutical Sciences, Dr. Andy Lewis, on May 20 at 10 AM London/11 AM Brussels or 6 PM London/1 PM New York for a live webinar on modified-release formulation…
Mitsubishi Chemical to Bolster Technology Platform Through Acquisition of American Organic & Inorganic Hybrid Chemicals
Mitsubishi Chemical Corporation recently announced its subsidiary Mitsubishi Chemical America, Inc. has entered into a definitive agreement to acquire all of the issued and….
Trio Pharmaceuticals & Ajinomoto Bio-Pharma Services Enter Development Collaboration for a Novel Antibody Therapeutic
Trio Pharmaceuticals, Inc. and Ajinomoto Bio-Pharma Services recently announced a development collaboration agreement to evaluate AJICAP, a proprietary site-specific conjugation technology offered by…
Stevanato Group Announces Product Development Collaboration With Cambridge Design Partnership on Pen-Injector Technology
Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for combination products and Cambridge Design Partnership (CDP), a UK- and US-based leading technology and product design partner, recently….
Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial
Avadel Pharmaceuticals plc recently announced positive topline data from its pivotal Phase 3 REST-ON trial assessing the safety and efficacy of FT218, an investigational, once-nightly…
Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Injection
Amphastar Pharmaceuticals, Inc. recently announced the US FDA has granted approval of its Abbreviated New Drug Application (ANDA) for Epinephrine Injection, USP 30 mg/30 mL…
Orchard Therapeutics Announces First Patient Dosed with OTL-201 Gene Therapy
Orchard Therapeutics recently announced that the first patient has been dosed in an open-label, proof-of-concept investigational study of OTL-201, an ex vivo autologous hematopoietic stem cell…
Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma
Harpoon Therapeutics, Inc. recently announced the first patient has been dosed with HPN217 in a Phase 1/2 clinical trial focused on relapsed, refractory multiple myeloma…
BioAegis Demonstrates Gelsolin Therapy Can Quell the COVID-19 Cytokine Storm & Promote Tissue Repair
BioAegis Therapeutics Inc. has highlighted recently published gene expression data in animal studies in which recombinant human plasma gelsolin (rhu-pGSN) significantly increased survival in pneumonia…
Santhera & Cold Spring Harbor Laboratory to Investigate Lonodelestat in COVID-19-Related ARDS
Santhera Pharmaceuticals recently announced it has entered into a collaboration agreement with Cold Spring Harbor Laboratory (CSHL) to investigate the potential of lonodelestat (POL6014), a…
Catalent Signs Agreement With Johnson & Johnson to be US Manufacturing Partner for Lead COVID-19 Vaccine Candidate
Catalent, Inc. recently announced a collaboration with the Janssen Pharmaceutical Companies of Johnson & Johnson, whereby Catalent’s Biologics business unit will accelerate availability of manufacturing capacity and…
Pivotal to Provide Specialized Clinical Research Services for New Clinical Trial With Patients That Have COVID-19
Pivotal recently announced it has been contracted to provide specialized clinical research services in a clinical trial to study the efficacy and safety of hyperimmune plasma, obtained from…
Histogen Announces Investigational Device Exemption Application
Histogen Inc. recently announced it has submitted an Investigational Device Exemption (IDE) application with the US FDA for the initiation of a….
Mogrify & Sangamo Announce Collaboration & Exclusive License Agreement
Mogrify Ltd and Sangamo Therapeutics recently announced they have executed a collaboration and exclusive license agreement for Sangamo to develop….
